{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:04:51Z","timestamp":1783911891506,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10620-025-09635-2","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T08:35:38Z","timestamp":1767429338000},"page":"2347-2354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in Length of Stay, Steroid Use and Colectomy Rates in Patients Admitted with Acute Severe Ulcerative Colitis: The Impact of Accelerated and Intensified Infliximab Dosing"],"prefix":"10.1007","volume":"71","author":[{"given":"Ryan","family":"Bartlett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Mohamedrashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiumaeswar","family":"Yogakanthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leya","family":"Nedumannil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifa","family":"Rawoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani","family":"Suleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soleiman","family":"Kashkooli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9149-3589","authenticated-orcid":false,"given":"Mayur","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"9635_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","volume":"4","author":"LC Dinesen","year":"2010","unstructured":"Dinesen LC, Walsh AJ, Protic MN et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4:431\u2013437. https:\/\/doi.org\/10.1016\/j.crohns.2010.02.001.","journal-title":"J Crohns Colitis."},{"key":"9635_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1136\/bmj.2.4884.375","volume":"2","author":"SC Truelove","year":"1954","unstructured":"Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2:375\u2013378. https:\/\/doi.org\/10.1136\/bmj.2.4884.375.","journal-title":"Br Med J."},{"key":"9635_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","volume":"5","author":"D Turner","year":"2007","unstructured":"Turner D, Walsh CM, Steinhart AH et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103\u2013110. https:\/\/doi.org\/10.1016\/j.cgh.2006.09.033.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9635_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2036.2007.03383.x","volume":"26","author":"CW Lees","year":"2007","unstructured":"Lees CW, Heys D, Ho GT et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26:411\u2013419. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03383.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"9635_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3310\/hta20440","volume":"1","author":"JG Williams","year":"2016","unstructured":"Williams JG, Alam MF, Alrubaiy L et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15\u201324. https:\/\/doi.org\/10.3310\/hta20440.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9635_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","volume":"380","author":"D Laharie","year":"2012","unstructured":"Laharie D, Bourreille A, Branche J et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909\u20131915. https:\/\/doi.org\/10.1016\/S0140-6736(12)61084-8.","journal-title":"Lancet."},{"key":"9635_CR7","doi-asserted-by":"publisher","first-page":"e61547","DOI":"10.7759\/cureus.61547","volume":"16","author":"A Salman","year":"2024","unstructured":"Salman A, Salman MA, Elewa A et al. Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis. Cureus. 2024;16:e61547. https:\/\/doi.org\/10.7759\/cureus.61547.","journal-title":"Cureus."},{"key":"9635_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:161\u2013170. https:\/\/doi.org\/10.1016\/S2468-1253(21)00377-0.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9635_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","volume":"9","author":"MC Choy","year":"2024","unstructured":"Choy MC, Li Wai Suen CFD, Con D et al. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:981\u2013996. https:\/\/doi.org\/10.1016\/S2468-1253(24)00200-0.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9635_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MEG.0000000000000753","volume":"29","author":"KM Johnsen","year":"2017","unstructured":"Johnsen KM, Goll R, Hansen V et al. Repeated intensified infliximab induction \u2013 results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm. Eur J Gastroenterol Hepatol. 2017;29:98\u2013104. https:\/\/doi.org\/10.1097\/MEG.0000000000000753.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"9635_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","volume":"149","author":"JF Brandse","year":"2015","unstructured":"Brandse JF, van den Brink GR, Wildenberg ME et al. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology. 2015;149:350\u2013355. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.016.","journal-title":"Gastroenterology."},{"key":"9635_CR12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/ecco-jcc\/jjv116","volume":"9","author":"JF Brandse","year":"2015","unstructured":"Brandse JF, Vos LM, Jansen J et al. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment. J Crohns Colitis. 2015;9:973\u2013981. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv116.","journal-title":"J Crohns Colitis."},{"key":"9635_CR13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/apt.13175","volume":"41","author":"MJ Rosen","year":"2015","unstructured":"Rosen MJ, Minar P, Vinks AA. Applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41:1094\u20131103. https:\/\/doi.org\/10.1111\/apt.13175.","journal-title":"Aliment Pharmacol Ther."},{"key":"9635_CR14","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","volume":"147","author":"OJ Adedokun","year":"2014","unstructured":"Adedokun OJ, Sandborn WJ, Feagan BG et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147:1296\u20131307. https:\/\/doi.org\/10.1053\/j.gastro.2014.08.035.","journal-title":"Gastroenterology."},{"key":"9635_CR15","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.cgh.2022.08.016","volume":"21","author":"KG Whaley","year":"2023","unstructured":"Whaley KG, Xiong Y, Karns R et al. Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2023;21:1338\u20131347. https:\/\/doi.org\/10.1016\/j.cgh.2022.08.016.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9635_CR16","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/ecco-jcc\/jjy028","volume":"12","author":"D Kevans","year":"2018","unstructured":"Kevans D, Murthy S, Mould DR et al. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. J Crohns Colitis. 2018;12:662\u2013669. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy028.","journal-title":"J Crohns Colitis."},{"key":"9635_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","volume":"13","author":"DJ Gibson","year":"2015","unstructured":"Gibson DJ, Heetun ZS, Redmond CE et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:330\u2013335. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.041.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9635_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/apt.15456","volume":"50","author":"S Sebastian","year":"2019","unstructured":"Sebastian S, Myers S, Argyriou K et al. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther. 2019;50:675\u2013683. https:\/\/doi.org\/10.1111\/apt.15456.","journal-title":"Aliment Pharmacol Ther."},{"key":"9635_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ibd\/izaa088","volume":"27","author":"RK Grant","year":"2021","unstructured":"Grant RK, Jones GR, Plevris N et al. The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis. Inflamm Bowel Dis. 2021;27:451\u2013457. https:\/\/doi.org\/10.1093\/ibd\/izaa088.","journal-title":"Inflamm Bowel Dis."},{"key":"9635_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18190","author":"A Croft","year":"2024","unstructured":"Croft A, Okano S, Hartel G et al. A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis. Aliment Pharmacol Ther. 2024. https:\/\/doi.org\/10.1111\/apt.18190.","journal-title":"Aliment Pharmacol Ther."},{"key":"9635_CR21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625\u20131629. https:\/\/doi.org\/10.1056\/NEJM198712243172603.","journal-title":"N Engl J Med."},{"key":"9635_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","volume":"9","author":"NM Noor","year":"2024","unstructured":"Noor NM, Lee JC, Bond S et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:415\u2013427. https:\/\/doi.org\/10.1016\/S2468-1253(24)00034-7.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9635_CR23","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1053\/j.gastro.2022.01.023","volume":"162","author":"N Krugliak Cleveland","year":"2022","unstructured":"Krugliak Cleveland N, Torres J, Rubin DT. What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented? Gastroenterology. 2022;162:1396\u20131408. https:\/\/doi.org\/10.1053\/j.gastro.2022.01.023.","journal-title":"Gastroenterology."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09635-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09635-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09635-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:26:29Z","timestamp":1783909589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09635-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["9635"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09635-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Northern Health Research Development and Governance Unit, with formal Ethics committee review not deemed to be required for this retrospective study (reference 2024_non-HREC_29).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}